NCT05029466View on ClinicalTrials.gov

Psilocybin for Treatment-Resistant Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

July 22, 2023

Study Completion Date

July 22, 2023

Conditions
Treatment Resistant Depression
Interventions
DRUG

Psilocybin

Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.

Trial Locations (1)

L5G 3H4

Canadian Rapid Treatment Centre of Excellence (CRTCE), Mississauga

Sponsors

Collaborators (1)

Braxia Scientific Corp.
All Listed Sponsors
collaborator

Braxia Scientific Corp.

UNKNOWN

collaborator

Usona Institute

OTHER

lead

Brain and Cognition Discovery Foundation

OTHER